RxDoctor Payments Data

Kimberly Larson

Women's Health · Medford, ORNPI 1972545978

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $754 of the $845 with a category attached, or 89.2%. 12 manufacturers reported payments, led by Astellas Pharma US Inc at 30.2% of the total. Reporting peaked in 2023 at $383 and has fallen 74.4% since, to $98 in 2025. Among women's health clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$845in general payments, 2019–2025

Across 31 payments — averaging $27.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$255
  • Novo Nordisk$125
  • AbbVie$123
  • Exact Sciences$78
  • Organon$62
  • Sumitomo Pharma America, Inc.$46
  • plus $156 from 6 others

What the payments were for

  • Food & beverage$75489%
  • Education$9111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$845 in reported general payments places this provider in the 90th percentile of 57 women's health providers in Oregon.

See all women's health providers in Oregon

Medicare billing

Part B allowed, 2024
$41,502
Medicare patients
209
Services billed
526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol282$12,993
Estradiol (Twice Weekly)Estradiol64$8,659
DottiEstradiol61$8,042
ProgesteroneProgesterone, Micronized184$7,435
GemtesaVibegron13$5,773
Estradiol (Once Weekly)Estradiol20$2,349
Clobetasol Propionate43$916
Levothyroxine Sodium95$845
ValacyclovirValacyclovir Hcl20$546
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip36$524
Testosterone Cypionate16$492
Ibandronate Sodium11$314
Acyclovir24$185
Escitalopram Oxalate11$163
Bupropion XlBupropion Hcl16$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$46$5,77313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 57 women's health providers in Oregon.

Other women's health in Medford

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →